Latest progress of chimeric antigen receptor modified T cells in the treatment of hematological malignancies

VernacularTitle:表达嵌合抗原受体修饰T细胞治疗血液系统恶性肿瘤的最新研究与进展
Author: Ping HOU ; Jianping LI
From: Chinese Journal of Tissue Engineering Research 2017;21(21):3438-3444
CountryChina
Language:Chinese
Abstract: BACKGROUND:In recent years, the use of chimeric antigen receptor modified T cells (CAR-T cells) has achieved good results in the treatment of hematological malignancies. OBJECTIVE:To summarize the CAR-T technology, and its anti-tumor mechamism, progress in the treatment of hematological malignancies as well as its safety and coping strategies. METHODS:A search of PubMed, CNKI, Wanfang by computer was performed for articles related to CAR-T published from January 2010 to January 2016, using the keywords of CAR-T in English and Chinese, respectively. RESULTS AND CONCLUSION:The main principles that CAR-T cells fight against tumors are as follows: (1) resistance to immune escape through down-regulation of MHC; (2) production of interleukin-6, -10 indirectly influences the growth of tumor cells; and (3) tumor microenvironment changes inhibit tumor growth. The use of CAR-T in the treatment of hematological malignancies has been developed by leaps and bounds in recent years. Current studies concerning B cell lymphoma mainly focus on anti-CD19 CAR-T cells that have certain therapeutic effects on acute myeloid leukemia and acute lymphoblastic leukemia. However, its safety and effectiveness have yet to be studied.